Page 46 - Ethical Guidelines for Conducting Research Studies Involving Human Subjects
P. 46

Herbal Substance:

                                 •       as above for Phase I/II trials.

                                 In addition:
                                 •       statement  that  the  plant  is  cultivated  according  to  Good
                                         Agricultural  Practices  or  harvested  according  to  Good
                                         Wild crafting Practices
                                 •       reference batch.

                                 Herbal Product:
                                 •       as above for Phase I/II trials

                                 In addition:
                                 •       environmental impact statement.

                                 This  relevant  information  should  be  included  in  the  protocol  for
                                 evaluation  of  these  products,  because  of  the  extensive  use  of
                                 traditional  AU  formulations  both  in  animals  and  humans,  which
                                 helps  in  analysis  of  the  chemistry,  manufacturing,  and  control  of
                                 the  product.  The  manufacture  of  the  product  should  ideally  be as
                                 per traditionally processed formulation to authorize the statement
                                 for efficacy as seen in traditional practice.
                                 It  is  claimed  that  the  extracts  of  herbal  products  and  AU
                                 formulations provide a therapeutic advantage, as they are mixture
                                 of  at  least  partially  uncharacterized  constituents  and  these
                                 unknown  constituents  may  be  additive  or  synergistic  in  action  or
                                 may  produce  a  balance  to  counteract  adverse  effects  of  any  one
                                 constituent.  This  may  thus  provide  more  efficacy  than  would  be
                                 provided by the known constituent alone. Thus, purification of the
                                 medicines down to known or otherwise single chemical constituents
                                 is not required as it may lead to loss of the advantage provided by
                                 the mixture.

                                  Analysis  of  the  active  pharmaceutical  ingredient(s)  may  be  best
                                 approached by analysis of one or more active biomarker(s), analysis
                                 of  a  chemical  constituent  that  constitutes  a  sizable  percentage  of
                                 the  total  ingredients,  and  a  chemical  fingerprint  of  the  total
                                 ingredients for standardization and quality control. The latter two
                                 analyses  would  act  as  replacements  for  analysis  of  the  unknown
                                 constituents  that  contribute  to  efficacy.  In  order  to  have  the  best
                                 standards by minimizing variation of  content from batch  to batch
                                 several analytical procedures may be needed to adequately quantify
                                 the constituents of herbal products or AU formulations.





                   BMRC ETHICAL GUIDELINE ON HUMAN SUBJECTS                                   Page 42
   41   42   43   44   45   46   47   48   49   50   51